間充質(zhì)干細(xì)胞（mesenchymal stem cells，MSCs）是一類來源于中胚層的成體干細(xì)胞，具有自我更新和多向分化的能力。zui常見的MSCs有：骨髓間充質(zhì)干細(xì)胞、脂肪間充質(zhì)干細(xì)胞、胎盤間充質(zhì)干細(xì)胞、羊膜間充質(zhì)干細(xì)胞、臍帶間充質(zhì)干細(xì)胞等。1995年，由惡性血液病患者的骨髓中獲得并經(jīng)體外培養(yǎng)得到的MSCs被移植回患者體內(nèi)，經(jīng)過臨床研究顯示這些干細(xì)胞的具有治療潛力，從此，對MSCs的研究由實(shí)驗(yàn)室進(jìn)入了臨床應(yīng)用。

目前，市面上MSCs細(xì)胞表面標(biāo)志物特性為：CD105、CD73、CD90等表面標(biāo)志物陽性表達(dá)，CD34、CD45等造血系細(xì)胞表面標(biāo)志物或人白細(xì)胞抗原HLA-DR、HLA-DP、HLA-DQ等則基本不表達(dá)。

除了上面提到的標(biāo)志物之外，還有沒有更多相關(guān)抗體呢？

艾美捷 Atlas Antibodies 間充質(zhì)干細(xì)胞標(biāo)志物抗體。

蛋白指標(biāo)               貨號               應(yīng)用類型

CD29/ITGB1 HPA059297 IHC, WB

CD105/ENG HPA011862 IHC, WB

CD73/NT5E HPA017357 IHC,WB,ICC-IF

CD90/Thy-1 HPA003733 IHC,ICC-IF

CD106/VCAM1 HPA069867 WB, ICC-IF

CD117/KIT AMAb90901 IHC, WB

CD146/MCAM HPA008848 IHC, WB

CD166/ALCAM HPA010926 IHC

CD44/PGP1 HPA005785 IHC,WB,ICC-IF

CD54/ICAM1 HPA002126 IHC, WB

CD56/NCAM1 HPA039835 IHC,WB,ICC-IF

CSPG4/NG2 HPA002951 IHC, WB

GDF-5/BMP14 HPA015648 IHC, WB

ITGA2B/CD41 HPA031170 IHC, WB

MYOG/MYF4 HPA028336 ICC-IF

OSX/SP7 HPA063202 IHC

RUNX2/AML3 HPA022040 IHC,WB,ICC-IF

RUNX3/AML2 HPA059006 IHC, WB

SOX11/SRY (sex determining region Y)-box 11 AMAb90501 IHC,WB,ICC-IF

SOX6/SRY-Box Transcription Factor 6 HPA001923 IHC,ICC-IF

SOX9/CMD1 HPA001758 IHC,WB,ICC-IF

* 僅適用于科研用途.

發(fā)表文章（摘取部分）：

1、Alcedo, Karel P., et al. "Tumor‐Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma."Hepatology communications10 (2019): 1400-1414.

2、Haun, Randy S., et al. "Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers."Cancer biology & therapy10 (2015): 1557-1565.

3、Serra, Sara, et al. "CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death."Blood, The Journal of the American Society of Hematology23 (2011): 6141-6152.

4、Ziebarth, Angela J., et al. "Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer."Clinical Cancer Research1 (2013): 170-182.